Open AI Drug Discovery Benchmarks

Insilico Medicine says it is opening core AI benchmarking tools around drug discovery and real experimental validation. The important mechanism is a possible shared evaluation layer between model builders and laboratories, not another drug-generation model. It remains a single organizational announcement; public benchmark access, external submissions, comparable wet-lab outcomes or adoption by another laboratory would confirm the category.